HASBROUCK HEIGHTS, NJ (July 28, 2010) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an update today on the Company’s Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety... (Source: Drugs.com - Clinical Trials)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Abstract  Benign prostatic hyperplasia (BPH) is the fourth most commonly diagnosed medical condition in older men. As a consequence, acute urinary retention can occur in patients with preoperative prostate cancer. Robot-assisted radical prostatectomy as a treatment modality for prostate cancer was designed to decrease operative morbidity and minimize long-term morbidity such as incontinence and erectile dysfunction. Three patients with prostate cancer coexisting with a BPH-related urinary retention managed with a clean intermittent catheterization (patient #1), and an indwelling Foley catheter (patients #2 and #3), were treated with a robot-assisted radical prostatectomy. After the procedure, the patients were able to void spontaneously, with good urine flow and reasonable ...

Conclusion Alpha-blockers, nonbenzodiazepine sleep aids, benzodiazepines, H(2)-blockers, lithium, atypical antipsychotics, atypical antidepressants, anticonvulsants and mood stabilizers, conventional anti-psychotics, laxatives and stool softeners, and dementia and Alzheimer's disease were significant predictors of inpatient falls in a psychiatric population. PMID: 20651318 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Conclusion: Our results indicate that the cytoplasmic stablization of HIF1alfa in NE-differentiated cells in benign and malignant prostate tissue is due to presence of an HIF1alfa isoform, HIF1alfa1.2. Co-localization of this isoform with HIF1beta indicated that the HIF1alfa1.2 isoform might sequester HIF1beta in the cytoplasm. (Source: BMC Cancer)

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE:524715) announced that USFDA has granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Flomax ®, tamsulosin capsules. These tamsulosin hydrochloride capsules, 0.4 mg are therapeutically equivalent to Flomax® Capsules 0.4 mg from Boehringer Ingelheim Pharmaceuticals, Inc. Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)... (Source: Health News from Medical News Today)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Study Suggests that SPET-085 May Be as Active as Leading Prescription Therapy - - Euromed Committed to Clinical Research to Offer Health Conscious Patients Alternative Health Maintenance Options - NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new... (Source: Drugs.com - Clinical Trials)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH). BPH, also known as an enlarged prostate, is the most common benign proliferative disorder in men, affecting more than 50 percent of men over the age of 70. Symptoms include urinary hesitancy, weak urine stream, nocturia, incontinence, and recurrent urinary tract infections... (Source: Health News from Medical News Today)

Abstract  The clinical significance of circulating follistatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M+) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy subjects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Conversely, in BPH patients, FLST levels resulted lower than in HS (...

Laser prostatectomy has evolved in the last 2 decades to become a viable and competitive option for open simple prostatectomy and transurethral resection of the prostate to treat obstructive symptomatic benign prostatic hyperplasia. There are 2 laser prostatectomy procedures, one of which uses a pure vaporization/ablation technique in which tissue is vaporized away in a systematic sweeping fashion. With the other procedure the prostate is resected into small pieces with the aid of a laser and/or a mechanical morcellator. What is clear is that the second procedure is more technically challenging. (Source: The Journal of Urology)

CONCLUSION: SPET-085 effectively inhibits the enzyme that has been linked to BPH, and the amount of extract required for activity is very low compared to data reported for other extracts. It can be concluded from data in the literature that SPET-085 is as effective as a hexane extract of saw palmetto that exhibited the highest levels of bioactivity, and is more effective than other SPEs tested. This study confirmed that SPET-085 has prostate health-promoting bioactivity that also corresponds favorably to that reported for the established prescription drug standard of therapy, finasteride. PMID: 20623347 [PubMed - as supplied by publisher] (Source: Advances in Therapy)

The FDA has granted 510(k) clearance for a liquid-cooled fiber to be used with the company's recently launched 180-watt laser system for the treatment of benign prostatic hyperplasia. Medscape Medical News (Source: Medscape Today Headlines)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.